Company Overview of AstraZeneca AB
AstraZeneca AB researches, develops, manufactures, and markets pharmaceuticals for gastrointestinal, cardiovascular, respiratory, and pain control. The company was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was founded in 1913 and is based in Sodertalje, Sweden. AstraZeneca AB operates as a subsidiary of AstraZeneca PLC.
Sodertalje, 151 85
Founded in 1913
Key Executives for AstraZeneca AB
Compensation as of Fiscal Year 2015.
AstraZeneca AB Key Developments
Cerulean Pharma Inc. Announces Clinical Collaboration with AstraZeneca AB and National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101
Nov 17 15
Cerulean Pharma Inc. announced that it has entered into a collaboration with AstraZeneca AB (AstraZeneca) and the National Cancer Institute (NCI), to study LYNPARZA™ (olaparib) and CRLX101. The collaboration will explore the synergistic effects of AstraZeneca’s LYNPARZA, a poly ADP ribose polymerase (PARP) inhibitor, and CRLX101, Cerulean’s inhibitor of topoisomerase 1 (Top1). The NCI will conduct a combination Phase I/IIa trial in the Branch led by Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch. The discovery of new, therapeutic combinations that improve patient outcomes is a core part of strategy. The combination of LYNPARZA with CRLX101 provides an opportunity to investigate the potential of LYNPARZA beyond patients with mutations in homologous repair genes such as BRCA. The scientific rationale for combining PARP inhibitors with Top1 inhibitors is well understood. Simply stated, Top1 inhibitors damage DNA, and PARP inhibitors prevent DNA damage repair. CRLX101 is a Top1 inhibitor. Top1 inhibitors trap DNA-topoisomerase complexes, preventing ligation and resulting in persistent single-stranded breaks. LYNPARZA is a PARP inhibitor that exploits tumor DNA damage repair pathway deficiencies to preferentially kill cancer cells. PARP’s main role is to detect and signal single-strand DNA breaks to the enzymatic complex that repairs single-strand DNA breaks. Under this collaboration, AstraZeneca will supply LYNPARZA, Cerulean will supply CRLX101, and the NCI will fund and conduct the clinical trial under Cooperative Research and Development Agreements with the companies. The clinical trial of LYNPARZA in combination with CRLX101 in small cell lung cancer will enroll approximately 55 patients with enrollment expected to commence in the first half of 2016.
AstraZeneca Announces Earnings Results for the Third Quarter of 2015
Nov 5 15
AstraZeneca announced earnings results for the third quarter of 2015. The company announced third quarter revenue fell 10% to $5.95 billion as competition from generic drugmakers hit sales. The company says profit more than tripled to $770 million from $254 million for the same period a year earlier.
AstraZeneca AB Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 through Sep-30-2015
Jul 31 15
AstraZeneca AB Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 through Sep-30-2015. Venue: Congress Center, Basel, Switzerland. Presentation Date & Speakers: Sep-29-2015, Christoph Pittius, VP, Head of Transactions, BD, Global Product and Portfolio Strategy. Sep-30-2015, Shane Maloney, Business Development Director, Tim Herpin, Head of Transactions team.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|